Pursuing whether PKCβ expression is predictive in breast cancer is critical because a number of PKCβ selective inhibitors have shown efficacy in pre-clinical and clinical trials for a multitude of cancer types (4, 60). The gene discussed is PRKCB; the disease is breast carcinoma.